ABSTRACT
To investigate the expression of multiple therapeutic targets in tissue specimens from patients with orbital inflammatory syndromes, the clinical records of 16 patients treated for orbital inflammation between January 2003 and November 2005 for whom tissue blocks were available were reviewed retrospectively. Immunohistochemical staining was performed on archived specimens using commercially available monoclonal antibodies against CD3, CD20, CD22, CD23, CD25, and CD52 antigens. The histologic diagnoses were confirmed, and the immunohistochemical staining patterns were agreed upon by both collaborating pathologists (JLJ and PC-B). The study included 13 women and 3 men who ranged in age from 4 to 79 years (mean, 46 years). The histologic diagnoses were as follows: orbital pseudotumor in six patients; sarcoidosis, three; eosinophilic granuloma, one; necrobiotic xanthogranuloma, one; nonspecified granulomatous inflammation, one; Graves' ophthalmopathy, one; Wegener's granulomatosis, one; and reactive lymphoid hyperplasia, two. One orbital lymphoma specimen and one foreign body reaction specimen were used as controls. CD20 was strongly expressed in all specimens except three (Wegener's granulomatosis, eosinophilic granuloma, and nonspecified granulomatous inflammation specimens), and CD25 was strongly expressed in all specimens except the Wegener's granulomatosis specimen, in which this antigen was only moderately expressed. CD20 and CD25 were strongly or moderately expressed in most of the tested specimens of orbital inflammation. If our findings are confirmed in a larger study, rituximab, which targets CD20, and denileukin diftitox (ONTAK), which targets CD25, should be considered for future clinical trials for orbital inflammatory syndromes.
Subject(s)
Antigens, CD/biosynthesis , Antigens, CD/genetics , Orbital Diseases/pathology , Orbital Diseases/therapy , Adult , Aged , Antibodies, Monoclonal/therapeutic use , Child, Preschool , Female , Humans , Inflammation/immunology , Inflammation/metabolism , Inflammation/therapy , Male , Middle Aged , Orbital Diseases/immunology , Orbital Pseudotumor/immunology , Orbital Pseudotumor/pathology , Orbital Pseudotumor/therapy , Retrospective Studies , SyndromeABSTRACT
BACKGROUND: The differential diagnosis of destructive lytic lesions of the spine includes amyloid tumors. The diagnosis of amyloid tumor with fine needle aspiration biopsy (FNA) is challenging. Previous reports of FNA of osseous amyloid tumors have detailed the cytologic appearance of amyloid along with lymphocytes, plasma cells and histiocytes, occasionally multinucleate or forming granulomatous lesions. CASE: An 84-year-old man presented with neck pain. Radiologic studies showed a destructive, lytic lesion of C-6, with a large, soft tissue mass. FNA yielded many acellular smears containing abundant amyloid that was confirmed with special stains of corresponding tissue cores and subsequent surgical biopsies. CONCLUSION: Osseous amyloid tumors are destructive, lytic lesions that mimic other processes. Amyloid can be distinguished from other substances in FNA samples and amyloid tumor identified, even when amyloid is present without typical cellular components.
Subject(s)
Amyloidosis/pathology , Biopsy, Needle , Cervical Vertebrae , Spinal Neoplasms/pathology , Aged , Amyloidosis/diagnostic imaging , Cervical Vertebrae/diagnostic imaging , Cervical Vertebrae/pathology , Humans , Male , Spinal Neoplasms/diagnostic imaging , Tomography, X-Ray ComputedABSTRACT
To investigate the immune consequences of intraocular administration of modified adenoviral vectors, C57BL/6 normal and retinal degeneration C57BL/6 (rd/rd) mice were immunized with subcutaneous, subretinal, vitreal, or anterior chamber injections of replication-deficient adenovirus (AdV) containing the Escherichia coli beta-galactosidase gene (AdV-LacZ). Fourteen days after the initial inoculation, the animals were immune challenged with an injection of AdV-LacZ in the right ear pinna. Antigen-induced delayed type hypersensitivity (DTH) was measured by determining relative ear swelling. Normal C57BL/6 mice immunized with subretinal, vitreal, or anterior chamber injections did not demonstrate a DTH response. The rd/rd C57BL/6 mice injected in the anterior chamber with the viral construct also did not respond with DTH in a manner similar to normal mice responding to intraocular injection and subsequent challenge. However, the rd/rd C57BL/6 mice immunized by the subretinal or vitreal route did respond to immune challenge with a DTH response. Histologic examination of the eyes showed a lack of infiltration by inflammatory cells. Although these results suggest that the potential for immune consequences is reduced when modified adenoviral vectors are used in the normal ocular environment, these vectors used in the vitreal cavity of rd/rd animals may induce a systemic response to the vectors.
Subject(s)
Adenoviridae/genetics , DNA, Viral/administration & dosage , DNA, Viral/immunology , Eye/immunology , Genetic Vectors/administration & dosage , Genetic Vectors/immunology , Retinal Degeneration/genetics , Animals , DNA, Viral/genetics , Ear/pathology , Eye/metabolism , Eye/pathology , Genetic Therapy/methods , Genetic Vectors/genetics , Hypersensitivity, Delayed/immunology , Hypersensitivity, Delayed/pathology , Inflammation/immunology , Inflammation/pathology , Injections/adverse effects , Injections, Subcutaneous/adverse effects , Lac Operon/genetics , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Retinal Degeneration/immunology , Retinal Degeneration/pathology , Retinal Degeneration/therapyABSTRACT
The present study was undertaken to analyse the relationship of lens glutathione (GSH) and light to cataract development in mice deficient in gamma-glutamyl transpeptidase (GGT). These mice have reduced levels of cysteine and GSH in the eye and develop cataracts. GGT-deficient mice raised under normal vivarium conditions, showed no cataractous changes at birth, but by 1 week they had developed nuclear opacities. By 3 weeks more severe cataracts develop, and lens GSH levels are approximately 6-7% of wild type levels. By 6-11 weeks cataracts show nuclear and cortical involvement, liquefaction and calcification. Single cell DNA electrophoresis (comet assay) demonstrated mild DNA damage in the lens epithelium. GGT-deficient mice raised in the dark beginning the day after conception all developed cataracts, but these were less severe than those in GGT-deficient mice raised with normal vivarium lighting. Administration of N -acetyl cysteine (NAC) raises lens GSH and almost completely prevents cataract development. Our data indicate that cataract development in GGT-deficient mice is multifactorial and results from exogenous damage (exposure to light), reduced lens GSH levels, and nutritional effects secondary to low cysteine levels.
Subject(s)
Cataract/enzymology , gamma-Glutamyltransferase/deficiency , Acetylcysteine/therapeutic use , Animals , Cataract/drug therapy , Cataract/etiology , Cysteine/physiology , Electrophoresis , Free Radical Scavengers/therapeutic use , Glutathione/physiology , Lighting , Mice , Mice, Inbred C57BLABSTRACT
To generate animal models of retinoblastoma that closely resemble metastatic and nonmetastatic human disease for the purposes of examining tumor biology and developing alternate treatments, human retinoblastoma cell lines were injected into the vitreal cavities of immunodeficient mice. Two reproducible animal models with contrasting biological behaviors analogous to human retinoblastoma have been developed. The Y79 retinoblastoma model demonstrated specific tumor evolution similar to that seen in human invasive and metastatic disease. Y79 retinoblastoma cells formed intraocular tumors that were initially confined to the vitreal cavity. Tumors progressively invaded the retina, subretinal space, choroid, optic nerve head, and anterior chamber of the eye. Tumors progressed into the subarachnoid space and focally invaded the brain. Metastases were detected in the contralateral optic nerve. Large tumors developed extraocular extensions. The histology of the tumors showed a poorly differentiated pattern with high mitotic rate, foci of necrosis, and calcification. The WERI-Rb model more closely resembled nonmetastatic human retinoblastoma. WERI- Rb tumors were localized in the eye with only anterior choroidal invasion at late stages. To examine potential biological differences in vitro, the retinoblastoma cell lines were cocultured with adherent choroid cells or adherent glioma cells which represent the targets of invasive retinoblastoma in vivo. Consistent with the in vivo observations, Y79 cells but not WERI-Rb cells adhere specifically to both the choroidal and the glioma cell lines.
Subject(s)
Retinal Neoplasms/pathology , Retinoblastoma/pathology , Retinoblastoma/secondary , Animals , Cell Adhesion , Cell Line , Choroid/cytology , Disease Models, Animal , Eye/pathology , Female , Glioma/pathology , Haplorhini , Humans , Infant , Mice , Neoplasm Transplantation , Rats , Retinal Neoplasms/physiopathology , Retinoblastoma/physiopathologyABSTRACT
OBJECTIVE: To report a case of corneal stromal infection caused by a protozoon of the genus MICROSPORIDIA:, including clinical, histopathologic, and electron microscopic observations. DESIGN: Case report. METHODS: Light and electron microscopy studies were performed on keratectomy specimens from a 67-year-old immunocompetent man who had a unilateral chronic stromal keratitis that was refractory to medical treatment. Initial corneal biopsy followed by lamellar and penetrating keratoplasty were performed on the patient. All the specimens were studied histopathologically. RESULTS: Light microscopy of the corneal biopsy and the subsequent keratectomy specimens demonstrated myriad small, round to oval microsporidial organisms measuring 3.5 to 5.0 micrometer in length that stained positively with the periodic acid-Schiff, Grocott-methenamine silver, and acid-fast methods and were gram positive. Electron microscopic observations demonstrated viable blastospores that had a thin osmiophilic outer cell wall and contained 11 to 13 coils of the filament. The light and electron microscopic features, the tinctorial characteristics, and the selective corneal stromal involvement are consistent with microsporidial keratitis. CONCLUSIONS: Microsporidiosis should be considered in the differential diagnosis of a culture-negative stromal keratitis refractory to medical treatment. The diagnosis can be easily established based on the morphologic features of the protozoa in the keratectomy specimens. No effective medical treatment for the stromal disease is available. Full-thickness keratoplasty is suggested because, in our patient, lamellar keratoplasty did not preclude recurrence of the disease.
Subject(s)
Corneal Stroma/parasitology , Eye Infections, Parasitic/parasitology , Keratitis/parasitology , Microsporida/isolation & purification , Microsporidiosis/parasitology , Aged , Animals , Biopsy , Corneal Stroma/ultrastructure , Diagnosis, Differential , Eye Infections, Parasitic/pathology , Humans , Keratitis/pathology , Keratoplasty, Penetrating , Male , Microscopy, Electron , Microsporida/ultrastructure , Microsporidiosis/pathologyABSTRACT
Low-grade intraosseous osteosarcoma is an uncommon and well-differentiated osteosarcoma with a good prognosis. We report a proximal tibial low-grade intraosseous osteosarcoma with a prominent intratumoral lymphoid infiltrate, which led to an initial diagnosis of probable malignant lymphoma. The importance of this infiltrate, which exhibited reactive features on flow cytometric studies, is not known. Our patient is free of tumor 1 year after limb salvage surgery, without hematologic or lymphoid abnormalities.
Subject(s)
Bone Neoplasms/pathology , Osteosarcoma/pathology , Adult , Biopsy, Needle , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/surgery , Disease-Free Survival , Female , Humans , Lymphatic Metastasis , Osteosarcoma/diagnostic imaging , Osteosarcoma/surgery , Radiography , Salvage Therapy , Treatment OutcomeSubject(s)
Cornea/parasitology , Corneal Diseases/parasitology , Eye Infections, Parasitic/parasitology , Immunocompetence , Microsporidiosis/parasitology , Nosema/isolation & purification , Aged , Animals , Cells, Cultured , Humans , Male , Nosema/growth & development , Nosema/ultrastructure , Spores/ultrastructureABSTRACT
Children presenting with large retinoblastomas are currently treated by enucleation. As most patients are young children, the long-term repercussions of such surgery are often devastating. Subsequent radiation or chemotherapy, although effective in managing residual tumor, greatly increase the probability of the development of second malignancies later in life. Smaller tumors can sometimes be managed with local cryo- or laser surgery, thus saving the eye. The hypothesis that gene therapy could be used to reduce the tumor size sufficiently to allow local control was tested using a murine model of retinoblastoma. Y79Rb human retinoblastoma cells can be killed in vitro when transduced with an adenoviral vector containing the herpes simplex thymidine kinase gene (AdV-TK) followed by treatment with the prodrug ganciclovir. Intravitreal injections of Y79Rb cells in immunodeficient mice produce an aggressive, metastatic murine model of retinoblastoma. When these murine retinoblastomas were transduced in vivo with AdV-TK and the animals treated with intraocular injections of ganciclovir, 70% showed a complete ablation of detectable tumor. Treated animals had a significant prolongation of progression-free survival as compared with untreated controls. Gene therapy effectively reduced the tumor burden in this murine model of retinoblastoma. Thus gene therapy, in conjunction with local surgical control, may provide an effective alternative to enucleation, systemic chemotherapy, or radiotherapy for treatment of large, nonmetastatic retinoblastomas in children.
Subject(s)
Eye Neoplasms/therapy , Ganciclovir/therapeutic use , Genetic Therapy , Retinoblastoma/therapy , Thymidine Kinase/genetics , Adenoviridae/metabolism , Animals , Ganciclovir/toxicity , HeLa Cells , Herpes Simplex/enzymology , Herpes Simplex/genetics , Humans , Mice , Mice, Knockout , Neoplasm Transplantation , Prodrugs/therapeutic use , Transduction, Genetic , Tumor Cells, CulturedABSTRACT
Mesoblastic nephroma (MN) is a distinctive tumor that is seen mostly in early infancy and that consists of classic and cellular (atypical) variants. Mesoblastic nephroma rarely occurs in adulthood, but MN in this age group still is poorly characterized because there are only 17 reported cases. We describe five additional cases of adult MN, including one case of the cellular variant, characterize the immunohistochemical profiles in detail, and critically review the previously reported cases. The collective data obtained from these 22 cases of adult MN showed that the patients predominantly were women (20 cases), ranging in age from 19 to 78 years, who were asymptomatic (5 cases) or had nonspecific signs and symptoms referable to a renal mass. Twenty tumors were classified as classic and 2 as cellular. The tumors were 2-24 cm, well circumscribed, and partially encapsulated and displayed a solid/ cystic cut surface, with a predominantly solid component in most tumors. One tumor, however, was almost purely cystic. Most tumors extended to the renal sinus. and some appeared entirely intrapelvic on imaging studies; however, gross and microscopic evaluation did not show destructive invasion of the pelvic wall. Extension of the tumor beyond the renal capsule has not been described. Each tumor was composed of epithelial and stromal components both. The epithelial component, which displayed no difference between the classic and cellular variants, was composed of isolated or clustered tubules and cysts lined by a benign epithelium with a wide range of cytologic differentiation. The stromal cells were composed of fibroblasts, myofibroblasts, and smooth muscle cells in various combinations. Stromal cellularity was low for the classic variant but high for the cellular variant. Hemorrhage, necrosis, and high mitotic index were noted in the stroma of the cellular, but not in the classic variant. Immunohistochemical study applied to the five current cases and seven normal control kidneys confirmed the presence of fibroblasts, myofibroblasts, smooth muscle cells, and prominent vessels in the stroma of each tumor. Most cysts and tubules within the tumors had a distinctive immunohistochemical profile, similar to that of collecting duct but different from those of other portions of the nephron in the normal control kidneys. After total or partial nephrectomy, without adjuvant chemotherapy or radiotherapy, 19 patients, including the 2 with cellular MN, were alive and well at 8-months to 48-years follow-up. Follow-up was not available in two patients. The remaining patient had recurrence at the surgical site 24 years after nephrectomy. Adult MN displays a distinctive morphologic spectrum that parallels that of its pediatric congener. It probably is a benign tumor that can be treated successfully by complete excision. The collecting duct differentiation expressed by most tubules and cysts of adult MN implies ureteric bud, which is the exclusive embryologic origin of collecting duct, as an important element in the histogenesis of this rare but fascinating type of tumor.
Subject(s)
Kidney Neoplasms/pathology , Nephroma, Mesoblastic/pathology , Adult , Aged , Biomarkers, Tumor/analysis , Disease-Free Survival , Female , Humans , Immunoenzyme Techniques , Kidney Neoplasms/chemistry , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/surgery , Male , Middle Aged , Neoplasm Recurrence, Local , Nephroma, Mesoblastic/chemistry , Nephroma, Mesoblastic/diagnostic imaging , Nephroma, Mesoblastic/surgery , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Failure of trabeculectomy is attributed to an exaggerated wound healing response at the episcleral level. We have developed a simple technique in mice that creates corneoscleral wounds and used it to study the role of growth factors in wound healing associated with loss of fistular patency. In addition, the effect of suramin on the wound healing response has been investigated. MATERIALS AND METHODS: Using black C57B1/6 mice, we created a fistula from the subconjunctival space to the anterior chamber by external penetration with a 25-gauge needle through the bulbur conjunctiva. Eyes were examined by light microscopy at different times following surgery and evaluated for the presence of growth factors in the sclerosing wound by immunohistochemistry. In an additional group, suramin (1.0 mg/ml) was applied topically five times. RESULTS: The limbal/scleral wounds closed rapidly. Granulation tissue consisting mostly of fibroblasts developed within the first 2 days, and the collagen component increased over time. By 4 weeks, the wound was completely healed. We found that within 1 day after surgery GF beta 2 reached high intensity. TGF beta 1 and PDGF A reached maximal intensity by day 2 and remained elevated for about a week, PDGF B was present at moderate intensity even before surgery. Myofibroblastic differentiation was observed from days 2 to 7. Suramin-treated wounds showed a decrease of cells and delay in fibroblast maturation. TGF beta 1 and TGF beta 2 levels persisted longer than in the controls, while PDGF A and PDGF B levels were lower than in the controls at all time points. CONCLUSIONS: The mouse corneoscleral wound model that we have developed mimics the process of wound healing and fistulizing surgery that takes place in other animal models and in human eyes in which the outcome of the surgery is poor. Our analysis of the appearance of growth factors associated with wound healing demonstrates that PDGF A as well as TGF beta 1 and TGF beta 2 appear early in the process at high levels and are potential targets for interventive strategies to ensure channel patency. Suramin has a distinct effect on the wound healing process and expression of growth factors and may be a promising substance for clinical use.
Subject(s)
Cornea/pathology , Filtering Surgery , Sclera/pathology , Wound Healing , Animals , Cornea/drug effects , Cornea/metabolism , Cornea/surgery , Disease Models, Animal , Female , Growth Substances/metabolism , Immunohistochemistry , Mice , Mice, Inbred C57BL , Ophthalmic Solutions , Sclera/drug effects , Sclera/metabolism , Sclera/surgery , Suramin/administration & dosage , Wound Healing/drug effectsABSTRACT
BACKGROUND: Trabeculectomies are the most frequently performed procedures in surgically treating eyes with glaucoma. Failures are caused by fibrosis in the external ostium of the filtering procedure. In order to inhibit the fibrotic wound healing reaction, a new pharmacological approach using suramin, which inhibits a variety of important growth factors was used. METHODS: Pigmented rabbits were used and filtering procedures performed. Suramin was applied with concentrations ranging from 10 mg/ml to 333 mg/ml once during surgery and four times following surgery. The success of the filtering procedure was assessed by intraocular pressure measurements. To evaluate possible intraocular toxic effects, treated eyes were histopathologically evaluated after 4 weeks, and the ciliary body adjacent to the site of application was examined using electron microscopy. RESULTS: With concentrations of suramin of 200 mg/ml and 333 mg/ml, the trabeculectomies were patent longer than in the controls and in eyes operated with mitomycin C, which currently is the most frequently used antiproliferative drug to enhance the outcome of surgery in humans. No severe toxic effects to the ciliary epithelium were seen in suramin treated eyes. CONCLUSIONS: This study demonstrates for the first time the efficiency of a substance that broadly inhibits the action of growth factors on target cells in the setting of ocular wound healing. In this in vivo model, suramin has been shown to be highly effective in preventing scarring and in having fewer toxic side effects than usually used antimetabolites. These results therefore may suggest a new approach to the surgical treatment of glaucoma.
Subject(s)
Glaucoma/surgery , Suramin/therapeutic use , Trabeculectomy , Wound Healing/drug effects , Animals , Electromyography , Female , Fibrosis , Filtering Surgery , Intraocular Pressure , Rabbits , Trabeculectomy/adverse effectsABSTRACT
BACKGROUND: The process of ocular wound healing with respect to glaucomatous filtering procedures is of current interest. Delaying this response in patients could possibly lead to more favorable surgical results. So far, only highly toxic antimetabolites have come into frequent clinical use. The possible efficacy of other groups of substances such as growth factor inhibitors has not yet been examined in vitro. METHODS: We exposed Tenon's capsule fibroblasts in tissue culture to various concentrations of decorin and suramin. The dose responses of type I and type III collagen to these inhibitors were measured using an ELISA-type dot blot assay. Total cellular protein production was assayed by measuring the incorporation of tritiated leucine. RESULTS: At a concentration of 10 micrograms/ml, suramin reduced the collagen production by more than 80%. Decorin, at a concentration of 100 micrograms/ml, reduced type I collagen production by about 50% while type III collagen was reduced by 80%. At these concentrations, the total cellular protein production was not inhibited. CONCLUSIONS: Both suramin and decorin, which specifically inhibit the action of growth factors on target cells, reduce the production of collagen synthesis by Tenon's capsule fibroblasts. This is a specific effect, because total protein production is not influenced. This sets these substances apart from antimetabolites. Decorin and suramin may have clinical relevance in that they appear to interfere with ocular wound healing more specifically than the substances so far frequently used.
Subject(s)
Antineoplastic Agents/pharmacology , Collagen/biosynthesis , Connective Tissue/metabolism , Proteoglycans/pharmacology , Suramin/pharmacology , Antineoplastic Agents/administration & dosage , Cell Line , Collagen/antagonists & inhibitors , Connective Tissue/drug effects , Connective Tissue Cells , Decorin , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Extracellular Matrix Proteins , Fibroblasts/cytology , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Proteoglycans/administration & dosage , Suramin/administration & dosage , Wound Healing/drug effectsABSTRACT
gamma-Glutamyl transpeptidase (GGT) is an ectoenzyme that catalyzes the first step in the cleavage of glutathione (GSH) and plays an essential role in the metabolism of GSH and GSH conjugates of carcinogens, toxins, and eicosanoids. To learn more about the role of GGT in metabolism in vivo, we used embryonic stem cell technology to generate GGT-deficient (GGTm1/GGTm1) mice. GGT-deficient mice appear normal at birth but grow slowly and by 6 weeks are about half the weight of wild-type mice. They are sexually immature, develop cataracts, and have coats with a gray cast. Most die between 10 and 18 weeks. Plasma and urine GSH levels in the GGTm1/GGTm1 mice are elevated 6-fold and 2500-fold, respectively, compared with wild-type mice. Tissue GSH levels are markedly reduced in eye, liver, and pancreas. Plasma cyst(e)ine levels in GGTm1/GGTm1 mice are reduced to approximately 20% of wild-type mice. Oral administration of N-acetylcysteine to GGTm1/GGTm1 mice results in normal growth rates and partially restores the normal agouti coat color. These findings demonstrate the importance of GGT and the gamma-glutamyl cycle in cysteine and GSH homeostasis.
Subject(s)
Cysteine/deficiency , Growth Disorders/enzymology , gamma-Glutamyltransferase/deficiency , Animals , Body Weight , Brain/growth & development , Brain/pathology , Crosses, Genetic , Eye/growth & development , Eye/pathology , Female , Genotype , Growth Disorders/genetics , Growth Disorders/pathology , Intestine, Small/enzymology , Kidney/enzymology , Male , Mice , Mice, Inbred C57BL , Mice, Inbred Strains , Mice, Knockout , Pancreas/enzymology , Recombination, Genetic , Restriction Mapping , Seminal Vesicles/enzymology , Sex Characteristics , gamma-Glutamyltransferase/genetics , gamma-Glutamyltransferase/metabolismABSTRACT
We targeted a mutant p53 gene (val135), previously shown to cause tumors in transgenic mice, to the kidney and eye using a gamma-glutamyltranspeptidase promoter. Although transgene RNA was expressed in both tissues, and mutant protein could be detected at high levels in the kidney and was appropriately localized to the nuclei of proximal tubules, no gross or microscopic lesions developed, even when mice were held as long as 75 weeks. When these mice were crossed with transgenic mice carrying HrasT24 (containing a codon 12 mutation) driven by the same promoter, the p53val135 transgene partially suppressed the mutant ras phenotype (proximal tubular hyperplasia and adenomas and carcinomas of the ciliary body and retinal pigment epithelium). The kidneys of double transgenic mice younger than 25 weeks showed less tubular hyperplasia and cystic change than littermates carrying gamma-glutamyltranspeptidase(I)rasT24 alone. By 33 weeks, there was no difference in the severity of the kidney lesions. The eye lesions were less aggressive, and no malignant lesions were identified. Our findings are consistent with the work of others, indicating that p53val135 is not tumorigenic under all conditions; in fact, in some circumstances, it retains some of the suppressing activity of wild-type p53.
Subject(s)
Genes, p53 , Mutation , Valine/genetics , Alanine/genetics , Animals , Base Sequence , Genes, ras , Mice , Mice, Transgenic , Molecular Sequence Data , RNA/analysis , Transgenes , Tumor Suppressor Protein p53/analysis , Tumor Suppressor Protein p53/genetics , gamma-Glutamyltransferase/geneticsABSTRACT
We studied the biodegradation of and the tissue reaction to microspheres of 50:50 poly(D,L-lactic-co-glycolic)acid (PLGA) (viscosity-average MW: 3000 d), injected intravitreous in rabbits. These microspheres are under investigation as injectable devices for intravitreous sustained drug delivery. The rate of intravitreous degradation of PLGA microspheres has not been well documented in the literature. Twenty two pigmented rabbits underwent gas vitrectomy in one eye: 19 eyes received 2.5 mg of PLGA microspheres in 1 ml of balanced salt solution (BSS) and 3 control eyes received 1 ml of BSS only. Slit lamp exam and indirect ophthalmoscopy were performed periodically from day 1 to 6 months after surgery. The eyes were enucleated and studied by light microscopy and immunohistochemistry at various time points. The electroretinogram (ERG) was recorded in a subgroup of rabbits before injection and after 1 and 6 months. The amount of microspheres in the vitreous cavity progressively decreased. At 6 months microspheres were found in 1/4 rabbits at indirect ophthalmoscopy and in 4/4 rabbits histopathologically. A mild localized, non progressive foreign body reaction was observed. The cell reaction was composed mostly of vimentin and glial fibrillary acidic protein positive cells which probably represent glial cells and fibroblasts. The choroid and retina were normal. The ERG showed no abnormalities. No clinical inflammatory signs were observed 4 days postoperatively and thereafter.
Subject(s)
Biocompatible Materials/pharmacology , Eye/drug effects , Lactic Acid , Microspheres , Polyglycolic Acid , Polymers/pharmacology , Vitreous Body/drug effects , Animals , Biocompatible Materials/adverse effects , Biocompatible Materials/pharmacokinetics , Biodegradation, Environmental , Drug Delivery Systems , Electroretinography/drug effects , Female , Foreign-Body Reaction/etiology , Foreign-Body Reaction/pathology , Male , Ocular Physiological Phenomena , Polylactic Acid-Polyglycolic Acid Copolymer , Polymers/adverse effects , Polymers/pharmacokinetics , Rabbits , Vitreous Body/metabolism , Vitreous Body/pathologyABSTRACT
BACKGROUND: Transcleral retinopexy may be applied with either a cryoprobe or the newer contact laser delivery systems. Tissue responses to these modalities are studied. METHODS: Transcleral 1064-nm continuous wave neodymium-ytrium-aluminum garnet (CW Nd:YAG) laser retinopexy lesions were compared with retinopexy lesions produced by a cryoprobe in a pigmented rabbit model. Equatorial transcleral CW Nd:YAG laser retinopexy or cryoretinopexy was applied. Rabbits were killed 1 day, 3 days, 1 week, or 1 month after treatment. Hematoxylin and eosin stains and immunohistochemical studies were conducted to determine the level of retinal damage and glial reaction. Antibodies against Müller cells (vimentin and glial fibrillary acidic protein), astrocytes (glial fibrillary acidic protein and S-100 protein), retinal pigment epithelial (RPE) cells (cytokeratin 8, 18, and 19 [5D3]), and macrophages (HAM 56) were used. RESULTS: Lesions produced by cryotherapy showed significant overlying retinal destruction with intravitreal RPE cell (5D3 positive) migration. Lesions produced by transcleral CW Nd:YAG laser showed reaction primarily at the level of choroidal melanocytes and RPE. Marked expression of both glial fibrillary acidic protein and vimentin epitopes with a normal expression of S-100 was seen in the chronic lesion made with cryotherapy and with less intensity in lesions made with CW Nd:YAG laser. CONCLUSION: Although less inner retinal destruction and no intravitreal RPE migration was observed in lesions formed by transcleral CW Nd:YAG laser, similar deep retinal Müller cell reaction occurred in lesions formed by both cryotherapy and laser as demonstrated by immunohistochemical studies.
Subject(s)
Cryosurgery , Laser Therapy , Retina/pathology , Retina/surgery , Animals , Cell Adhesion , Choroid/metabolism , Choroid/pathology , Choroid/surgery , Immunoenzyme Techniques , Intermediate Filament Proteins/metabolism , Macrophages/metabolism , Macrophages/pathology , Pigment Epithelium of Eye/metabolism , Pigment Epithelium of Eye/pathology , Rabbits , Retina/metabolism , S100 Proteins/metabolism , Sclera , Wound HealingABSTRACT
We examined eye lesions in five lines of transgenic mice carrying the human rasT24 oncogene driven by the type I gamma glutamyl transferase (gamma GT) promoter. In three lines, hyperplasia developed as early as 11.5 days postconception in the outer neuroectodermal layer, which gives rise to ciliary body and retinal pigment epithelium. At birth, the eyes from many animals contained adenomas, and by day 27, mice developed invasive adenocarcinomas originating in the region of the ciliary body. Microphthalmia, cataracts, and chronic nongranulomatous inflammation involving the anterior and/or posterior segments of the eye were also found. gamma GT is detectable histochemically as early as 11.5 gestational days in the outer neuroectodermal layer and after birth is more abundant in the ciliary body than in the retinal pigment epithelium. Using a reverse transcriptase-polymerase chain reaction, we found that type I (but not types II or III) gamma GT RNA is made by the mouse eye; the gamma GT(I)rasT24 transgene transcription product was detected in the eyes of all five transgenic lines. The sequential progression of hyperplasia to invasive neoplasms in the ciliary body in response to gamma GT(I)rasT24 expression differs from the process in the kidney of these animals in which tubular hyperplasia and microadenomas with little evidence of progression are the major lesions.